Abstract: Abstract Monoclonal antibodies (mAbs) to human TRAIL receptors (TRAIL-Rs) have been developed in tumor targeted therapy and currently used in clinical Ⅰ-Ⅳ trials . MAbs can bind death-receptors（TRAIL-R1 and TRAIL-R2）and then results in formation of the death inducing signaling complex (DISC) and apoptosis of tumor cells. TRAIL-Rs mAbs have become one of the research and development hotspots of anti-tumor drugs . These mAbs have achieved remarkable results in combination with radio- or chemo-therapy drugs or other agents and immunotherapy in the treatment of tumor and offer a new therapy strategy for clinical tumor treatment.

Key words: TRAIL, TRAIL receptors, Human mAb, Tumor therapy